Douglas Feinstein

Dr. Feinstein is Research Professor in the Department of Anesthesiology at the University of Illinois in Chicago; holds a position as a Research Biologist at the Jesse Brown VA Medical Center in Chicago, and is a recent recipient of a prestigious VA Research Career Scientist award. His research centers on mechanisms and treatments for neurodegenerative diseases including Multiple Sclerosis and Alzheimer’s disease. He has been continuously funded by Federal agencies, non-for-profit societies, and pharmaceutical companies for over 25 years, and has published over 160 peer-reviewed scientific papers. He serves as Associate Editor or Handling Editor on 8 neuroscience journals boards; serves on grant review panels for the NIH, the VA, and for organizations including the National MS Society and the Alzheimer’s association; and was previously the president of the American Society for Neurochemistry, where he currently serves as Treasurer. He is a co-founder of EnSol Therapeutics

Israel (Rudi) Rubinstein

Dr. Rubinstein is Professor of Medicine, University of Illinois at Chicago, Attending Physician, University of Illinois Hospital & Health Sciences System and Jesse Brown VA Medical Center and Associate Chief of Staff for R&D, Jesse Brown VA Medical Center, Chicago, Illinois, USA. He holds several issued and pending US and international patents and has authored more than 200 peer-reviewed scientific papers. He is Editor-in-Chief, Nanotechnology, Science and Applications, Clinical Editor, Nanomedicine: Nanotechnology, Biology and Medicine and Associate Editor, International Journal of Nanomedicine. Dr. Rubinstein co-founded ResQ Pharma, Inc. that has recently submitted an IND application to the US FDA, and EnSol Therapeutics, LLC. Dr. Rubinstein is Board Member and Director of Advanced Life Sciences, a publicly-traded biopharmaceutical company in Woodridge, Illinois, USA.